Sitagliptin and alogliptin go head-to-head in Japan
This article was originally published in Scrip
Executive Summary
MSD/Ono's oral antidiabetic Januvia/Glactiv (sitagliptin) has been approved in Japan for use in combination with alpha-glucosidase inhibitors, putting its label on a par with that of its main competitor.